Please login to the form below

Not currently logged in
Email:
Password:

GSK in Sirtris takeover

Sirtris Pharmaceuticals has been taken over by GlaxoSmithKline (GSK) as part of an agreement involving the acquisition of the company's research portfolio through a cash tender offer of £11.33 per share
Sirtris Pharmaceuticals has been taken over by GlaxoSmithKline (GSK) as part of an agreement involving the acquisition of the company's research portfolio through a cash tender offer of £11.33 per share.

The agreement means GSK will pay Sirtris $720m (£362m), which specialises in the development of medicines to treat conditions related to the ageing process. Through the deal, GSK hopes to enhance its metabolic, neurological, immunologic and inflammation research capabilities.

Moncef Slaoui, chairman of GSK R&D, said: "This acquisition continues GSK's strategy of pursuing the best new science, externally or internally, to bring new medicines to patients and value to the GSK pipeline. Our intent is to retain all Sirtris employees and continue the entrepreneurial and innovative culture they created."

Sirtris will become part of GSK's drug discovery organisation and is expected to continue operating from its laboratories in Massachusetts, acting as an autonomous research unit.

Dr Christoph Westphal, CEO and vice-chair of Sirtris, said: "We expect this transaction will accelerate our vision to target sirtuins to treat diseases of metabolism and ageing and deliver tremendous value to patients, our shareholders and our employees."

6th May 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics